GlassScriptPhysician profile
Sarah M Gabel
NPI 1255594305
$2,281.83
in general payments reported to CMS, 2019-2025
30 companies · $332 in 2025
The $332 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $247 · 2020: $92.27 · 2021: $421 · 2022: $258 · 2023: $381 · 2024: $550 · 2025: $332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,264.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $408.83 | 2021-2025 | |
| Amgen INC. | $314.38 | 2019-2025 | Evenity, Prolia, Repatha |
| Novartis Pharmaceuticals Corporation | $286.25 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $153.53 | 2019-2025 | Breztri, Airsupra |
| Lilly USA, LLC | $137.20 | 2021-2025 | Mounjaro, Zepbound |
| Grifols USA, LLC | $92.30 | 2024-2025 | Prolastin-C Liquid |
| Pfizer INC. | $88.40 | 2021-2024 | |
| Novo Nordisk INC | $86.93 | 2019-2023 | Wegovy |
| E.R. Squibb & Sons, L.L.C. | $73.66 | 2024 | Eliquis |
| Dexcom, INC. | $64.04 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $62.18 | 2021-2022 | |
| Biogen, INC. | $52.51 | 2024 | Zurzuvae |
| Sanofi Pasteur INC. | $50.31 | 2023-2025 | |
| Electromed, INC. | $41.87 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $39.95 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Conmed Corporation | $34.26 | 2019 | |
| Glaxosmithkline, LLC. | $33.93 | 2022-2023 | Bexsero, Arexvy, Pediarix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.28 | 2019-2020 | |
| Insulet Corporation | $31.44 | 2024-2025 | Omnipod |
| Astellas Pharma US INC | $26.72 | 2023 | Veozah |
| Ge Healthcare | $26.01 | 2025 | |
| Daiichi Sankyo INC. | $24.42 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $20.28 | 2021 | |
| Organon LLC | $19.17 | 2024 | |
| Abbott Laboratories | $14.24 | 2023 | Freestyle Libre 2 |
| Exact Sciences Corporation | $14.22 | 2024 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $14.03 | 2021 | |
| Melinta Therapeutics, LLC | $13.08 | 2023 | Orbactiv, Kimyrsa |
| Sunovion Pharmaceuticals INC. | $12.89 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Gabel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.